Disease Overview
Why RA Demands Specialized BRA
The ORAL Surveillance trial fundamentally changed the RA treatment landscape by revealing cardiovascular and malignancy risks with JAK inhibitors, requiring comprehensive class-level safety monitoring and comparative BRA against TNF inhibitors.
JAK Inhibitor Cardiovascular Risk
The ORAL Surveillance study demonstrated increased MACE and VTE risk with tofacitinib vs. TNF inhibitors in patients age 50+ with cardiovascular risk factors. This led to FDA black box warnings across the JAK inhibitor class and EMA Article 20 referral, requiring ongoing comparative cardiovascular BRA for all JAK inhibitors.
Infection Risk Across Biologics
All RA therapies modifying immune function carry infection risks: tuberculosis reactivation (TNF inhibitors), herpes zoster (JAK inhibitors), progressive multifocal leukoencephalopathy (rituximab). Comparative infection safety profiling across mechanism classes requires integrated data from clinical trials and real-world evidence.
Biosimilar Switching Safety
With adalimumab, etanercept, infliximab, and rituximab biosimilars now widely available, safety monitoring during originator-to-biosimilar switching requires anti-drug antibody tracking, immunogenicity assessment, and efficacy maintenance monitoring in switched populations.
Platform Capabilities
How ArcaScience Addresses RA BRA Challenges
Our platform integrates RA-specific data covering JAK inhibitors, biologics, and biosimilars with AI models for cardiovascular risk, infection signal detection, and comparative class-level safety analysis.
RA Data Coverage
2,800+ RA clinical trials including ORAL Surveillance, SELECT, RA-BEAM, RA-BEYOND, and FINCH datasets. Comprehensive post-marketing data for tofacitinib, baricitinib, upadacitinib, adalimumab, etanercept, and 25+ other RA agents. Real-world evidence from RA registries including CORRONA, RABBIT, and NOR-DMARD.
Explore Data Engine →RA-Specific AI Models
AI models for cardiovascular risk stratification in JAK inhibitor-treated patients, comparative infection risk across mechanism classes, VTE signal detection, malignancy surveillance, and biosimilar immunogenicity tracking. BRAT framework with RA-specific regulatory precedent from ORAL Surveillance FDA advisory committee deliberations.
Explore AI Models →RA Regulatory Outputs
PSURs with cardiovascular safety deep-dives, RMPs with MACE/VTE monitoring protocols and risk minimization measures, comparative BRA reports vs. TNF inhibitor comparators, and HEOR reports supporting access negotiations for JAK inhibitors with updated safety positioning post-ORAL Surveillance.
Explore Outputs →RA Intelligence
Platform Performance in Rheumatoid Arthritis
RA adverse event data points
Faster CV signal detection for JAK inhibitors
Mechanism classes compared simultaneously
RA regulatory submissions supported
Case Evidence — RA
Post-ORAL Surveillance JAK Inhibitor Safety Monitoring
Challenge
Following the ORAL Surveillance results and FDA black box warning, a JAK inhibitor manufacturer needed to conduct accelerated benefit-risk reassessment across all approved indications (RA, PsA, UC) with comparative cardiovascular safety analysis against TNF inhibitors to support label update discussions with FDA and EMA.
Result
ArcaScience delivered cross-indication BRA integrating clinical trial and real-world cardiovascular data within 6 weeks, identifying patient subgroups with favorable benefit-risk profiles and supporting the company's regulatory strategy for maintaining broader access while implementing appropriate risk minimization measures.
Cross-indication BRA delivery
Indications analyzed simultaneously
VP, Global Drug Safety
Top-15 Pharma Company
Frequently Asked Questions